Catalyst Pharmaceuticals Correlations
CPRX Stock | USD 22.34 0.41 1.87% |
The current 90-days correlation between Catalyst Pharmaceuticals and Enliven Therapeutics is 0.32 (i.e., Weak diversification). The correlation of Catalyst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Catalyst Pharmaceuticals Correlation With Market
Very weak diversification
The correlation between Catalyst Pharmaceuticals and DJI is 0.4 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Catalyst Pharmaceuticals and DJI in the same portfolio, assuming nothing else is changed.
Catalyst |
Moving together with Catalyst Stock
0.69 | ESPR | Esperion Therapeutics | PairCorr |
0.74 | EWTX | Edgewise Therapeutics | PairCorr |
0.68 | BHC | Bausch Health Companies | PairCorr |
0.66 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
0.7 | EBS | Emergent Biosolutions | PairCorr |
0.87 | GILD | Gilead Sciences | PairCorr |
0.76 | MNMD | Mind Medicine | PairCorr |
Moving against Catalyst Stock
0.72 | HLN | Haleon plc | PairCorr |
0.7 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.68 | TAK | Takeda Pharmaceutical | PairCorr |
0.66 | ZTS | Zoetis Inc | PairCorr |
0.58 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
0.58 | RDY | Dr Reddys Laboratories | PairCorr |
0.55 | LLY | Eli Lilly Sell-off Trend | PairCorr |
0.53 | ELAN | Elanco Animal Health Potential Growth | PairCorr |
0.5 | PFE | Pfizer Inc Aggressive Push | PairCorr |
0.69 | ANRO | Alto Neuroscience, | PairCorr |
0.44 | CTLT | Catalent | PairCorr |
0.39 | ANEB | Anebulo Pharmaceuticals | PairCorr |
0.37 | LTRN | Lantern Pharma | PairCorr |
0.35 | DRMAW | Dermata Therapeutics | PairCorr |
0.35 | AMGN | Amgen Inc | PairCorr |
0.31 | CVS | CVS Health Corp Aggressive Push | PairCorr |
Related Correlations Analysis
-0.05 | -0.75 | 0.07 | 0.85 | 0.44 | CUE | ||
-0.05 | 0.57 | 0.54 | 0.08 | -0.01 | TFFP | ||
-0.75 | 0.57 | 0.34 | -0.65 | -0.27 | ELYM | ||
0.07 | 0.54 | 0.34 | 0.14 | -0.16 | INBX | ||
0.85 | 0.08 | -0.65 | 0.14 | 0.16 | ELVN | ||
0.44 | -0.01 | -0.27 | -0.16 | 0.16 | MOLN | ||
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Catalyst Stock performing well and Catalyst Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Catalyst Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
CUE | 7.68 | 1.25 | 0.19 | 1.35 | 5.91 | 20.27 | 67.78 | |||
TFFP | 6.89 | (1.75) | 0.00 | (1.33) | 0.00 | 11.28 | 95.77 | |||
ELYM | 3.87 | (0.92) | 0.00 | (2.63) | 0.00 | 6.21 | 34.87 | |||
INBX | 2.30 | 0.11 | 0.02 | 0.27 | 2.70 | 5.54 | 16.80 | |||
ELVN | 1.96 | 0.09 | 0.04 | 0.20 | 2.06 | 5.84 | 12.96 | |||
MOLN | 4.53 | (0.20) | 0.00 | (0.02) | 0.00 | 9.38 | 52.92 |
Catalyst Pharmaceuticals Corporate Management
Philip Schwartz | Co Sec | Profile | |
CMA CPA | VP, Officer | Profile | |
Pete Sr | Vice Sales | Profile | |
Mary Coleman | VP Relations | Profile | |
Stanley MD | Senior Discovery | Profile | |
Gary MD | Chief Officer | Profile |